ITCI - Intracellular Th - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46116X1019
Schizophrenia, Bipolar, Depression, Parkinson's, Dementia, Pain
Intra-Cellular Therapies, Inc. is a biopharmaceutical company dedicated to developing innovative small molecule drugs that address significant medical needs in neuropsychiatric and neurological disorders.
The company's primary focus is on targeting intracellular signaling mechanisms in the central nervous system (CNS), with the goal of creating effective treatments for complex conditions. One of their flagship products is CAPLYTA, a medication approved for the treatment of schizophrenia and bipolar depression in adults.
Intra-Cellular Therapies has a robust pipeline of promising drug candidates, including Lumateperone, which is currently in Phase 3 clinical trials for the treatment of depressive disorders and other neuropsychiatric indications. Additionally, the company is developing Lenrispodun (ITI-214) to address Parkinson's disease, CNS, and other disorders.
Other key pipeline projects include ITI-1284, aimed at treating neuropsychiatric disorders and behavioral disturbances in dementia, and ITI-333, which targets substance use disorders, pain, and psychiatric comorbidities such as depression, anxiety, and sleep disorders.
Founded in 2002, Intra-Cellular Therapies, Inc. is headquartered in New York, New York, and is committed to advancing the understanding and treatment of complex CNS disorders. For more information, visit their website at https://www.intracellulartherapies.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ITCI Stock Overview
Market Cap in USD | 8,011m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2014-01-07 |
ITCI Stock Ratings
Growth 5y | 94.5 |
Fundamental | -55.0 |
Dividend | |
Rel. Performance vs Sector | 1.84 |
Analysts | 4.44/5 |
Fair Price Momentum | 102.40 USD |
Fair Price DCF | - |
ITCI Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
ITCI Growth Ratios
Growth Correlation 3m | -8.2% |
Growth Correlation 12m | 75.3% |
Growth Correlation 5y | 94% |
CAGR 5y | 52.66% |
CAGR/Mean DD 5y | 2.82 |
Sharpe Ratio 12m | 1.30 |
Alpha vs SP500 12m | 26.23 |
Beta vs SP500 5y weekly | 0.94 |
ValueRay RSI | 68.51 |
Volatility GJR Garch 1y | 34.08% |
Price / SMA 50 | 2.99% |
Price / SMA 200 | 7.35% |
Current Volume | 650.9k |
Average Volume 20d | 457.6k |
External Links for ITCI Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 76.82 with a total of 650,915 shares traded.
Over the past week, the price has changed by -0.12%, over one month by +4.80%, over three months by -1.75% and over the past year by +54.38%.
According to ValueRays Forecast Model, ITCI Intracellular Th will be worth about 113.4 in October 2025. The stock is currently trading at 76.82. This means that the stock has a potential upside of +47.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 96.2 | 25.2 |
Analysts Target Price | 77.8 | 1.31 |
ValueRay Target Price | 113.4 | 47.7 |